Partner

Articles & Insights / Photostability

Photostability Studies That Separate Light Effects from Heat Effects

A product can remain acceptable in a temperature-controlled chamber and still change when exposed to light. Photostability studies identify this vulnerability and establish whether formulation, handling or packaging controls are needed.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Define what the study must establish
  • Characterise the light exposure
  • Include a meaningful dark control

Define what the study must establish

Start by distinguishing exploratory light stress from confirmatory photostability testing. Exploratory work investigates sensitivity and degradation pathways. Confirmatory work evaluates behaviour under a defined exposure and helps determine the need for protective measures. A harsh screening experiment may help rank prototypes without supporting the final packaging conclusion.

ICH Q1B provides the established pharmaceutical photostability framework. The consolidated ICH Q1 document was still listed by FDA as draft guidance when checked for this collection. Select the adopted requirements for the relevant market, and distinguish pharmaceutical expectations from those applicable to foods, nutraceuticals or cosmetics. R35R24

Characterise the light exposure

Light intensity and duration jointly determine exposure, but visible and ultraviolet energy are different measurements. Lux hours describe visible illumination weighted to human visual response. Watt hours per square metre describe radiant energy over the specified spectral region. One cannot be substituted for the other through an arbitrary numerical conversion.

Under the Q1B confirmatory approach, the overall illumination is at least 1.2 million lux hours and the integrated near-ultraviolet exposure is at least 200 watt hours per square metre. The selected source, exposure measurement and sample arrangement must satisfy the relevant approach; placing samples under an unspecified lamp for a fixed number of days does not demonstrate compliance. R35

Include a meaningful dark control

Light sources can warm the sample. A suitably protected dark control helps separate photochemical change from change caused by temperature or other study conditions. Its placement and protection should be planned so that it provides a reasonable comparison. Record temperature and relevant environmental observations during exposure.

The illustration shows the interpretive logic. If exposed samples change while comparable dark controls remain stable, light becomes a leading explanation. If both change, investigate the contribution of heat, preparation and background instability. The control supports interpretation; it does not remove the need to understand unequal sample temperatures or other experimental differences.

Explore the sciencePhotostability

Compare light exposure with a dark control

Exposed sampleDark controlRecord temperature
Exposed sample

Measure exposure and temperature, and assess relevant chemical and physical change.

Conceptual explanation. No product result, acceptance criterion or universal regulatory sequence is established by this illustration.

Exposed samples and suitable dark controls help distinguish light-related change from heat and background instability. This conceptual comparison does not replace control of sample presentation, exposure and temperature.

Make sample presentation representative

Layer thickness, container geometry, orientation and mixing can affect how much of a sample receives light. A powder spread thinly may behave differently from a deep powder bed. A liquid in a laboratory vessel may have a different light path and oxygen exposure from the marketed bottle. Describe these differences when drawing conclusions.

A sequence of unprotected product, immediate packaging and, where relevant, the complete marketed pack can help locate the level at which protection becomes effective. The conclusions apply to the tested materials and configuration. An amber appearance alone does not establish adequate spectral protection for every light-sensitive compound.

Select measurements that reveal the relevant change

Evaluate appearance alongside chemical and functional attributes. Discolouration may be visible before substantial potency loss, while a degradant can increase without a visible change. Use suitable stability-indicating methods and ensure that sample handling after exposure does not continue or obscure the reaction.

A hypothetical botanical liquid might darken under light with a small change in its principal marker. Investigate fingerprint changes, relevant degradation signals and packaging protection before deciding that the colour change is merely cosmetic. Conversely, a colour difference alone does not establish a safety consequence without further evidence.

Translate the result into product controls

If protection is needed, evaluate formulation adjustments, opaque or light-filtering packaging and handling instructions. Confirm the selected configuration with representative product. Routine laboratory preparation may also require light control if sample solutions degrade during analysis. That analytical precaution addresses measurement reliability and should be documented separately from consumer storage instructions.

Stabicon can integrate photostability studies with analytical evaluation and packaging assessment so that observed changes lead to specific, supported product decisions.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R35
    ICH Q1B Photostability Testing of New Drug Substances and Products

    Final guideline, 1996. Pharmaceutical light-exposure and study-design framework.

  2. R24
    FDA Q1 Stability Testing of Drug Substances and Drug Products

    Draft guidance, June 2025, as listed when checked. Not for implementation.

  3. R04
    ICH Q2 R2 Validation of Analytical Procedures

    Final guideline adopted November 2023. Analytical validation framework.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin